Veracyte Appoints New CMO, Elects Directors
Ticker: VCYT · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1384101
| Field | Detail |
|---|---|
| Company | Veracyte, Inc. (VCYT) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-of-directors, corporate-governance
Related Tickers: VCYT
TL;DR
Veracyte just named a new CMO and added two directors to the board.
AI Summary
Veracyte, Inc. announced on June 12, 2024, the appointment of Dr. Richard M. Klausner as Chief Medical Officer and the election of Dr. Klausner and Ms. Jennifer L. D. Smith to its Board of Directors. The company also reported on the outcome of its annual meeting of stockholders, where all nominated directors were elected and a proposal to ratify the appointment of its independent registered public accounting firm was approved.
Why It Matters
These executive and board changes could signal a strategic shift or enhanced focus in Veracyte's medical and governance operations.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters and executive appointments, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Veracyte, Inc. (company) — Registrant
- Dr. Richard M. Klausner (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Ms. Jennifer L. D. Smith (person) — Elected to Board of Directors
- June 12, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for Veracyte, Inc.?
Dr. Richard M. Klausner has been appointed as the new Chief Medical Officer for Veracyte, Inc.
Who were elected to Veracyte, Inc.'s Board of Directors?
Dr. Richard M. Klausner and Ms. Jennifer L. D. Smith were elected to Veracyte, Inc.'s Board of Directors.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 12, 2024.
What was the outcome of Veracyte, Inc.'s annual meeting of stockholders regarding director elections?
All nominated directors were elected at Veracyte, Inc.'s annual meeting of stockholders.
Was the appointment of Veracyte, Inc.'s independent registered public accounting firm ratified?
Yes, the proposal to ratify the appointment of Veracyte, Inc.'s independent registered public accounting firm was approved.
Filing Stats: 819 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-13 16:27:29
Key Financial Figures
- $0.001 — h registered Common Stock, par value, $0.001 per share VCYT The Nasdaq Stock Marke
Filing Documents
- vcyt-20240612.htm (8-K) — 46KB
- ex1018-k06x12x2024.htm (EX-10.1) — 192KB
- 0001384101-24-000093.txt ( ) — 397KB
- vcyt-20240612.xsd (EX-101.SCH) — 2KB
- vcyt-20240612_lab.xml (EX-101.LAB) — 22KB
- vcyt-20240612_pre.xml (EX-101.PRE) — 13KB
- vcyt-20240612_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. The stockholders of the Company voted on the following proposals at the Annual Meeting: 1. The following directors were nominated to serve until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified: For Against Abstain Broker Non-Votes Muna Bhanji 61,780,051 6,036,666 27,484 3,236,452 Marc Stapley 67,220,523 610,755 12,923 3,236,452 Each of the two nominees for director was elected to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified. 2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2024: For Against Abstain 70,832,239 230,683 17,731 The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. 3. The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers: For Against Abstain Broker Non-Votes 64,610,097 3,179,578 54,526 3,236,452 The stockho lders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers. 4. The approval of the 2023 Plan Amendment : For Against Abstain Broker Non-Votes 45,241,870 22,565,308 37,023 3,236,452 The stockho lders approved the 2023 Plan Amendment .
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 2023 Equity Incentive Plan, as Amended* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 13, 2024 VERACYTE, INC. By: /s/ Rebecca Chambers Name: Rebecca Chambers Title: Chief Financial Officer (Principal Financial Officer)